Scarica l'app Stockscreener
0.725
27.19%
0.155
Dopo l'orario di chiusura:
.72
-0.005
-0.69%
Biofrontera Inc Borsa (BFRI) Ultime notizie
Guidance Update: Can Biofrontera Inc Equity Warrant stock maintain growth trajectoryWeekly Earnings Recap & Growth Oriented Trading Recommendations - moha.gov.vn
Retail Trends: Will Biofrontera Inc. stock split again soonJuly 2025 Summary & Weekly Top Gainers Alerts - Улправда
Is Biofrontera Inc. stock a top momentum playMarket Risk Report & Expert Verified Movement Alerts - Улправда
Will Biofrontera Inc. stock split again soonMarket Activity Report & Accurate Trade Setup Notifications - Улправда
How Biofrontera Inc. Equity Warrant stock benefits from tech adoption2025 Dividend Review & Daily Profit Maximizing Tips - Улправда
How interest rate cuts could boost Biofrontera Inc. Equity Warrant stockGlobal Markets & AI Driven Stock Reports - Улправда
Will Biofrontera Inc. stock reach all time highs in 2025Profit Target & Long Hold Capital Preservation Plans - Улправда
Why Biofrontera Inc. stock remains resilientInflation Watch & Verified Swing Trading Watchlists - Улправда
Can Biofrontera Inc. Equity Warrant stock maintain growth trajectory2025 Support & Resistance & Reliable Momentum Entry Alerts - DonanımHaber
Will Biofrontera Inc. stock outperform Nasdaq indexWeekly Stock Analysis & Free Weekly Chart Analysis and Trade Guides - DonanımHaber
Biofrontera completes transfer of FDA approvals for Ameluz and RhodoLED By Investing.com - Investing.com South Africa
How Biofrontera Inc. stock reacts to global recession fearsGold Moves & Expert Curated Trade Setups - Улправда
Biofrontera completes transfer of FDA approvals for Ameluz and RhodoLED - Investing.com
Biofrontera completes transfer of Ameluz® and Rhodoled® FDA approval - marketscreener.com
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio - The Manila Times
Biofrontera Inc. Completes Transfer of Ameluz® and - GlobeNewswire
Book value per share of Biofrontera Inc. Warrant 2021-27.10.26 on Biofrontera – NASDAQ:BFRIW - TradingView — Track All Markets
Aug Levels: Will Biofrontera Inc Equity Warrant stock split attract more investorsPortfolio Performance Summary & AI Enhanced Trading Alerts - moha.gov.vn
What analysts say about Biofrontera Inc AI10 stockContrarian Investment Ideas & Free Daily Top Stock Picks for All Investors - earlytimes.in
Biofrontera (NASDAQ:BFRI) Trading Down 1.5% – Time to Sell? - Defense World
Biofrontera Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Biofrontera completes phase 1 study for expanded Ameluz treatment areas By Investing.com - Investing.com Nigeria
Will Biofrontera Inc. (AI10) stock sustain bullish trend into 2025Market Growth Review & Risk Controlled Swing Alerts - Newser
Why Biofrontera Inc. (AI10) stock attracts HNW investors2025 Big Picture & Safe Entry Momentum Tips - Newser
Why Biofrontera Inc. (AI10) stock is favored by hedge fundsWeekly Trade Analysis & Daily Oversold Stock Bounce Ideas - Newser
Will Biofrontera Inc. Equity Warrant stock outperform growth indexes2025 Investor Takeaways & Risk Controlled Stock Pick Alerts - Newser
Biofrontera completes final patient visit in Phase 1 PK study of Ameluz gel - TipRanks
Biofrontera completes phase 1 study for expanded Ameluz treatment areas - Investing.com
Biofrontera (Nasdaq: BFRI) wraps Ameluz Phase 1 PK trial on trunk, plans 2026 FDA sNDA - Stock Titan
Biofrontera files sNDA for Ameluz-PDT in treatment of sBCC - MSN
Can Biofrontera Inc. (AI10) stock survive global slowdownJuly 2025 Update & High Yield Stock Recommendations - Newser
Why Biofrontera Inc. stock remains on buy listsWatch List & Long Hold Capital Preservation Plans - Newser
Biofrontera Inc. (BFRI) 5.8% in After-hours: Filing for New Drug Application Boosts Stock - Stocks Telegraph
Biofrontera submits sNDA to FDA for skin cancer treatment By Investing.com - Investing.com Australia
Biofrontera Inc. (BFRI) 20.51% in After-hours: Notable Price Surge - Stocks Telegraph
Biofrontera submits sNDA to FDA for skin cancer treatment - Investing.com
Biofrontera Inc. announces filing of supplemental new drug application - marketscreener.com
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT - The Manila Times
Biofrontera Inc. Announces Filing of Supplemental New Drug - GlobeNewswire
Why global investors buy Biofrontera Inc. (AI10) stockJuly 2025 Selloffs & AI Enhanced Trading Alerts - Newser
Biofrontera (BFRI) files sNDA as Ameluz-PDT shows 65.5% clearance in sBCC trial - Stock Titan
Biofrontera (BFRI) Stock Analysis Report | Financials & Insights - Benzinga
2.19%
0.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):